SciTech Development Advances to Next Stage of Clinical Trial for ST-001 nanoFenretinide NEWS PROVIDED BY SciTech Development 13 Jan, 2025, 09:00 ET **Encouraging Data from Accelerated Trial Supports Progress for T-cell Non-Hodgkin Lymphoma.** DETROIT, Jan. 13, 2025 /PRNewswire/ — SciTech Development, a clinical-stage pharmaceutical company specializing in oncology, is pleased to announce the initiation…
Scitech Development Welcomes Ken Massey Ph.D., as Strategic Operations Advisor NEWS PROVIDED BY SciTech Development 10 Dec, 2024, 09:00 ET DETROIT, Dec. 10, 2024 /PRNewswire/ — SciTech Development is thrilled to welcome Ken Massey, Ph.D., as Strategic Operations Advisor. With a wealth of experience in drug development, Dr. Massey has played a pivotal role in…
Scitech Development Announces Promising Preliminary Results in Phase 1a Trial for T-cell Non-Hodgkin Lymphoma NEWS PROVIDED BY SciTech Development 03 Dec, 2024, 10:00 ET **Multiple Early Partial Responses Alongside Encouraging Safety and Pharmacokinetic Data** DETROIT, Dec. 3, 2024 /PRNewswire/ — SciTech Development, a clinical-stage pharmaceutical company focused on advancements in cancer treatment, is excited…
SciTech Development Welcomes John Chapman to the Strategic Advisory Board as Senior Financial Advisor NEWS PROVIDED BY SciTech Development 15 Oct, 2024, 09:00 ET DETROIT, Oct. 15, 2024 /PRNewswire/ — SciTech Development, Inc., a clinical-stage biotechnology company focused on innovative cancer therapeutics, is pleased to announce the addition of John Chapman, CPA, to its Strategic Advisory…
SciTech Development, Inc. Announces Receipt of Drug Supply From The National Cancer Institute (NCI) NEWS PROVIDED BY SciTech Development 17 Sept, 2024, 09:00 ET DETROIT, Sept. 17, 2024 /PRNewswire/ — SciTech Development, Inc., a clinical-stage biotechnology company focused on innovative cancer therapeutics, is pleased to announce that the National Cancer Institute (NCI), part of the National…
SciTech Development Raises Additional $3.2M to Expand Clinical Trials for CancerSciTech accelerates its mission to bring ST-001 to cancer patients. NEWS PROVIDED BY SciTech Development, LLC 04 Jun, 2024, 09:00 ET GROSSE POINTE FARMS, Mich., June 4, 2024 /PRNewswire/ — SciTech Development, a clinical-stage, specialty oncology pharmaceutical company, today announced it has closed an additional…
SciTech Development Announces First Patient Dosed in Phase 1 Clinical Trial of ST-001This study is designed to evaluate ST-001 for the treatment of T-cell non-Hodgkin’s lymphoma (NHL). NEWS PROVIDED BY SciTech Development, LLC 20 Dec, 2023, 08:00 ET GROSSE POINTE, Mich., Dec. 20, 2023 /PRNewswire/ — SciTech Development (“SciTech” or the “Company”), a clinical-stage pharmaceutical…
Learn about the Promise of ST-001 from Medical Experts – Catch the SciTech Roundtable Replay Here CONTACT David Schaffer
SciTech Development Announces The Formation of a Distinguished Medical Advisory Board With Top Oncology Specialists NEWS PROVIDED BY SciTech Development, LLC 26 Oct, 2023, 10:00 ET GROSSE POINTE FARMS, Mich., Oct. 26, 2023 /PRNewswire/ — SciTech Development, LLC, today announced the formation of a distinguished and independent medical advisory board (MAB) comprised of key opinion…
SciTech Readies for First-In-Human Trial with Clinical Supply of ST-001 nanoFenretinide NEWS PROVIDED BY SciTech Development, LLC 03 Oct, 2023, 17:19 ET GROSSE POINTE FARMS, Mich., Oct. 3, 2023 /PRNewswire/ –.SciTech announced today that it has successfully manufactured the clinical supply of its lead drug candidate, ST-001 nanoFenretinide, to initiate its upcoming clinical trial in T-cell…